Aurinia Pharmaceuticals Inc. (AUPH) income statement
AUPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 13/3058% below fair value
$15.13−0.27 (-1.75%)
Close on Nov 18, 2026Market cap $2.03BP/E 6.6Yield –
Aurinia Pharmaceuticals Inc. income statement
Ratios
Latest available, balances at Sep 30, 2026
Profitability, TTM
- Gross margin
- 90.6%
- Operating margin
- 48.6%
- Net margin
- 97.7%
- Return on equity, FY2025
- 59.9%
Financial strength
- Current ratio
- 6.12
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 47.7%
Valuation
- P/E ratio
- 6.6
- Price to sales
- 6.30
- Price to book
- 3.08
- Dividend yield
- –
See a number that looks wrong?